Shares of Thermo Fisher Scientific TMO remained unaffected after the company reported Q2 results.
Quarterly Results
Earnings per share rose 43.96% over the past year to $5.60, which beat the estimate of $5.49.
Revenue of $9,273,000,000 higher by 34.06% from the same period last year, which beat the estimate of $8,770,000,000.
Guidance
The upcoming fiscal year's EPS expected to be between $22.07 and $22.07.
The upcoming fiscal year's revenue expected to be between $35,900,000,000 and $35,900,000,000.
Conference Call Details
Date: Jul 28, 2021
Time: 08:30 AM
Technicals
52-week high: $534.50
52-week low: $401.06
Price action over last quarter: Up 12.77%
Company Profile
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (17%); life science solutions (38%); and lab products and services (38%).
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.